VEGFA and metastatic malignant neoplasm: VEGF-specific monoclonal antibody/nanobody is the first anti-angiogenic agent that was approved by Food and Drug Administration (FDA) in 2004 and its effectiveness has been proven in several metastatic cancers (45).